Short Interest in Lisata Therapeutics, Inc. (NASDAQ:LSTA) Declines By 28.2%

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 17,100 shares, a decline of 28.2% from the October 15th total of 23,800 shares. Based on an average daily trading volume, of 12,000 shares, the short-interest ratio is currently 1.4 days. Approximately 0.3% of the company’s shares are sold short.

Lisata Therapeutics Trading Up 0.7 %

Shares of NASDAQ:LSTA traded up $0.02 during midday trading on Thursday, reaching $2.81. The company had a trading volume of 3,975 shares, compared to its average volume of 13,598. The company’s 50 day moving average price is $2.97 and its 200 day moving average price is $3.09. Lisata Therapeutics has a 52-week low of $2.05 and a 52-week high of $3.83. The stock has a market cap of $23.38 million, a P/E ratio of -1.11 and a beta of 1.22.

Lisata Therapeutics (NASDAQ:LSTA) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.61) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.14. During the same quarter in the prior year, the business posted ($0.50) earnings per share. Research analysts forecast that Lisata Therapeutics will post -2.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Lisata Therapeutics in a research note on Wednesday, September 18th.

Hedge Funds Weigh In On Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP boosted its stake in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the period. Dimensional Fund Advisors LP owned about 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent reporting period. 8.94% of the stock is owned by hedge funds and other institutional investors.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.